Chemo-immunotherapy then surgery or radiation for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two standard treatments for esophageal cancer that has responded to initial chemo-immunotherapy: surgery to remove the tumor or radiation combined with chemotherapy. The goal is to see which approach offers better outcomes and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with esophageal cancer that can be surgically removed.
- You completed 2-3 cycles of induction chemo-immunotherapy (a PD-1 inhibitor plus taxane and platinum) and your tumor shrank significantly or disappeared.
- You are well enough to undergo daily activities (ECOG performance status 0-1) and have adequate organ function.
- You have not had prior surgery for esophageal cancer, major surgery within 4 weeks, or active autoimmune disease requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy plus immunotherapy first, followed by standard chemoradiation, for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this approach improves outcomes.
This study tests a combination of chemotherapy and immunotherapy before and after standard chemoradiation for people with locally advanced esophageal squamous cell carcinoma. It aims to see if this approach can improve outcomes with manageable side effects.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This study tests whether giving radiation therapy based on how well the tumor responds to initial chemoimmunotherapy can improve outcomes for people with a certain type of esophageal cancer. The goal is to find a more personalized treatment approach that may be more effective and possibly reduce side effects.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (serplulimab and nimotuzumab) given before surgery for a certain type of esophageal cancer. It aims to see if this approach can safely improve outcomes.
This trial tests whether combining two immunotherapy drugs (which boost your immune system to fight cancer) with a standard chemotherapy drug before surgery can improve outcomes for people with esophageal cancer that can be removed. The goal is to see if this approach shrinks the tumor and helps you live longer.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.